Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (151-160 of 266) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma CohortsSumanta K Pal, Yohann Loriot, Andrea Necchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2024
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, et al.
European Urology|October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with RucaparibAndrea Loehr, Arif Hussain, Akash Patnaik, et al.
Oncotarget|October 31, 2015
A Polycomb-mir200 loop regulates clinical outcome in bladder cancerMónica Martínez-Fernández, Marta Dueñas, Andrew Feber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder CancerVíctor G Martínez, Carolina Rubio, Mónica Martínez-Fernández, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 15, 2023
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trialMiguel Ángel Climent, Carlos Álvarez, Rafael Morales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerM Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Expert Opinion on Drug Safety|May 25, 2017
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studiesDaniel Castellano, José Pablo Maroto, Enrique Espinosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Pageof 27

Showing results (151-160 of 266) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma CohortsSumanta K Pal, Yohann Loriot, Andrea Necchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2024
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, et al.
European Urology|October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with RucaparibAndrea Loehr, Arif Hussain, Akash Patnaik, et al.
Oncotarget|October 31, 2015
A Polycomb-mir200 loop regulates clinical outcome in bladder cancerMónica Martínez-Fernández, Marta Dueñas, Andrew Feber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder CancerVíctor G Martínez, Carolina Rubio, Mónica Martínez-Fernández, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 15, 2023
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trialMiguel Ángel Climent, Carlos Álvarez, Rafael Morales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerM Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Expert Opinion on Drug Safety|May 25, 2017
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studiesDaniel Castellano, José Pablo Maroto, Enrique Espinosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Pageof 27